Literature DB >> 3871770

Human tumor necrosis factor. Production, purification, and characterization.

B B Aggarwal, W J Kohr, P E Hass, B Moffat, S A Spencer, W J Henzel, T S Bringman, G E Nedwin, D V Goeddel, R N Harkins.   

Abstract

Human tumor necrosis factor (TNF) was purified to homogeneity from serum-free tissue culture supernatants of the HL-60 promyelocytic leukemia cell line induced by 4 beta-phorbol 12-myristate 13-acetate. The purification scheme consisted of controlled-pore glass and DEAE-cellulose chromatography, Mono Q-fast-protein liquid chromatography, and reverse-phase high performance liquid chromatography. The purified protein was homogeneous by the criteria of sodium dodecyl sulfate-polyacrylamide gel electrophoresis and NH2-terminal sequence analysis. The specific activity of purified tumor necrosis factor is approximately 10(8) units/mg. The protein has a molecular weight of approximately 17,000, an isoelectric point of 5.3, and contains two cysteines involved in a disulfide bridge. Approximately 50% homology between TNF and another cytolytic lymphokine, lymphotoxin, exists when the NH2-terminal 34 residues of TNF and internal sequence generated by tryptic, Staphylococcus aureus V8 protease, and chymotryptic digests of TNF are aligned with the complete amino acid sequence of lymphotoxin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871770

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  196 in total

Review 1.  Antimicrobial defense of the earthworm.

Authors:  M Bilej; P De Baetselier; A Beschin
Journal:  Folia Microbiol (Praha)       Date:  2000       Impact factor: 2.099

2.  Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice.

Authors:  N S Postma; R C Hermsen; D J Crommelin; W M Eling; J Zuidema
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Combination of recombinant cytokines fails to produce ex vivo expansion of human blood hematopoietic progenitor cells.

Authors:  Y Takaue; T Abe; Y Kawano; A Hirao; A Yokobayashi; Y Okamoto; S Saito; T Shimizu; J Sato; T Watanabe
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

4.  Optimization of cell culture conditions for production of biologically active proteins.

Authors:  S Hosoi; H Miyaji; M Satoh; T Kurimoto; A Mihara; N Fujiyoshi; S Itoh; S Sato
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

Review 5.  Tumor necrosis factor-α signaling in macrophages.

Authors:  Narayanan Parameswaran; Sonika Patial
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

6.  Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis.

Authors:  R D Curran; T R Billiar; D J Stuehr; J B Ochoa; B G Harbrecht; S G Flint; R L Simmons
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

7.  Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice.

Authors:  P M Waring; L J Waring; T Billington; D Metcalf
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Tumour necrosis factor in synovial exudates.

Authors:  F S Di Giovine; G Nuki; G W Duff
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

9.  Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage.

Authors:  Jorge Berlanga; Pedro Prats; Diadelis Remirez; Ricardo Gonzalez; Pedro Lopez-Saura; Jorge Aguiar; Miriam Ojeda; Joseph J Boyle; Anthony J Fitzgerald; Raymond J Playford
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.

Authors:  D Pennica; J S Hayflick; T S Bringman; M A Palladino; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.